Introduces the functionality and benefits of the first and only transgenic chicken producing single-domain antibodies to antibody industry thought leaders and research scientists from around the world

OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb^™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231214937823/en/

(Photo: Business Wire)

“Our recent launch of OmnidAb is the latest example of OmniAb’s commitment to innovation and the intelligent expansion of our technology. OmnidAb is the first and only transgenic chicken that produces single-domain antibodies, which represent an important class due to their unique physical properties that can be leveraged for a variety of important applications,” said Matt Foehr, Chief Executive Officer of OmniAb. “Several current partners are already leveraging OmnidAb in active programs while many others have expressed interest in this platform given its versatility in important applications, including alternate routes of administration, diagnostic applications and therapeutic approaches beyond what is typically possible with conventional antibodies.”

The OmnidAb transgenic chicken novel host system builds upon the success of the Company’s OmniChicken^® legacy by expressing an optimized single-domain human framework that can generate modular building blocks well suited to support a variety of therapeutic modalities. OmnidAb antibodies target distinct epitopes and have favorable developability profiles with high expression levels in mammalian cells. Compared with traditional antibodies, sdAbs produced by OmnidAb chickens have a compact format that opens new opportunities and broad clinical applications.

“We believe the OmnidAb platform offers significant benefits due to its built-in use of an optimized human scaffold combined with efficient in vivo affinity maturation. This minimizes the need for downstream engineering and provides a functionally diverse immune repertoire that is unavailable from mammalian systems. There is growing industry interest in this modality, and we look forward to working with partners to advance their programs leveraging our new OmnidAb technology,” added Bill Harriman, Ph.D., Senior Vice President, Antibody Discovery of OmniAb.

OmniAb is showcasing OmnidAb and its entire technology stack at the 2023 Antibody Engineering & Therapeutics Conference at booth #300 at the Marriott Marquis San Diego Marina.

In addition, the Company will be highlighting its OmniDeep^™ suite of in silico tools at the Conference in a presentation titled “Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep” on Friday, December 15^th at 12:05 p.m. Pacific time. OmniDeep integrates the Company’s Biological Intelligence^™ with AI and uses in silico tools to better mine diverse immune repertoires. Bob Chen, Senior Director, Discovery Systems, will present a case study showcasing OmniDeep’s ability to empower large-scale antibody discovery while selecting high-affinity clones. OmniAb is leveraging its technology stack to offer partners new discovery workflows and optimization tools for existing discovery campaigns. For more information about OmniAb’s proprietary technologies, please visit www.omniab.com or contact our business development team at bd@omniab.com.

About OmniAb^®

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence^™ (BI) of our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic^® (transgenic rat) and OmniClic^® (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur^™ features unique structural attributes of cow antibodies for complex targets. OmnidAb^™ is an in vivo platform for single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep^™, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.

The OmniAb suite of technologies span from BI-powered repertoire generation to cutting-edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

Forward-Looking Statements

OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: statements regarding the growth prospects of our business and the discovery needs of the pharmaceutical industry; the expected performance of, our technologies and the opportunities they may create; and the ability to add new partners and programs. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions, may have serious adverse consequences on our business, financial condition and stock price; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231214937823/en/